The adaptor protein STING (Stimulator of Interferon Genes) plays a central role in recognition of aberrant DNA as well as cyclic dinucleotides (CDN) from bacterial sources. The development of compounds that modulate STING has recently been the focus of intense research for the treatment of cancer, infectious disease as well as vaccine adjuvants. Numerous efforts have focused on the development of cyclic dinucleotide derivatives with few examples progressing into clinical trials in patients with solid accessible tumors amenable to intratumoral delivery. In this talk, we will report the discovery and development of a novel small molecule non-CDN STING agonist which is active across different human haplotypes and mouse STING, and functions as a systemically efficacious treatment of tumors in mice.

Dimerization of amidobenzimidazoles as STING receptor agonists for the treatment of cancer

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.